Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawn Brubaker

Orthopaedic Surgery Redding, CA Doctor of Osteopathy

NPI 1356473078 CMS profile 198267

2510 Airpark Dr, Ste 301, Redding, CA 96001

Open in the dashboard

General payments

$48,059

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawn Brubaker of Redding, CA is reported in the CMS Open Payments database as having received $48,059 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,765 3
2024 General $425 5
2023 General $4,900 9
2022 General $14,422 13
2021 General $658 13
2020 General $1,067 6
2019 General $19,822 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawn Brubaker
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Shawn Brubaker were reported at $6,765. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Shawn Brubaker Orthopaedic Surgery median Middle half National median
2019 $19,822 $644 $140–$2,844 $163
2020 $1,067 $312 $75–$1,860 $114
2021 $658 $520 $117–$2,495 $132
2022 $14,422 $598 $128–$2,731 $149
2023 $4,900 $461 $128–$2,264 $160
2024 $425 $497 $134–$2,475 $164
2025 $6,765 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $39,135 29 payments
  2. DePuy Synthes Products, Inc. $6,786 11 payments
  3. DePuy Synthes Sales Inc. $722 9 payments
  4. Stryker Corporation $689 18 payments
  5. Orthalign Inc $450 4 payments
  6. Aesculap Implant Systems, LLC $142 1 payment
  7. Baxter Healthcare $33 1 payment
  8. Merck Sharp & Dohme Corporation $33 1 payment
  9. Flexion Therapeutics, Inc. $19 1 payment
  10. Myoscience Inc. $18 1 payment
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $40,393 11 payments
  2. Travel and Lodging $4,883 17 payments
  3. Food and Beverage $2,783 50 payments
Products named General payments · program years 2019–2025
  1. PINNACLE Ortho-Hip $17,183 9 payments
  2. CORAIL Ortho-Hip $17,063 8 payments
  3. RECLAIM Ortho-Hip $17,063 8 payments
  4. RECLAIM Ortho-Hip $14,443 10 payments
  5. CORAIL Ortho-Hip $13,586 7 payments
  6. PINNACLE Ortho-Hip $13,278 5 payments
  7. ATTUNE $5,616 12 payments
  8. Velys $1,740 7 payments
  9. ORTHALIGN PLUS $450 4 payments
  10. MAKO $363 11 payments
  11. Other $1,535 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

755

Median for Orthopedic Surgery: 203

Drug cost

$27,476

Median for Orthopedic Surgery: $1,433

Branded share of claims

39.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $8,750
Xarelto Rivaroxaban Brand 13 $7,696
Celecoxib Generic 299 $7,233
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 166 $2,292
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 92 $853
Ondansetron Hcl Generic 39 $217
Cephalexin Generic 28 $116
Meloxicam Generic 33 $93
Tramadol Hcl Generic 19 $69
Naproxen Generic 15 $57

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$399,501

Of which drugs: $540

Medicare patients

446

Average age 73

Services billed

1,749

274 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 25%
Ischemic heart disease 23%
Chronic kidney disease 19%
Depression 18%
Atrial fibrillation 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 112 $75

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record